These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 22357577)

  • 1. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial.
    Ambrosy AP; Vaduganathan M; Huffman MD; Khan S; Kwasny MJ; Fought AJ; Maggioni AP; Swedberg K; Konstam MA; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2012 Mar; 14(3):302-11. PubMed ID: 22357577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
    Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
    Khan SS; Campia U; Chioncel O; Zannad F; Rossignol P; Maggioni AP; Swedberg K; Konstam MA; Senni M; Nodari S; Vaduganathan M; Subacius H; Butler J; Gheorghiade M;
    Am J Cardiol; 2015 Mar; 115(6):790-6. PubMed ID: 25728846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF.
    Samsky MD; Dunning A; DeVore AD; Schulte PJ; Starling RC; Tang WH; Armstrong PW; Ezekowitz JA; Butler J; McMurray JJ; Teerlink JR; Voors AA; Metra M; Mentz RJ; O'Connor CM; Patel CB; Hernandez AF
    Eur J Heart Fail; 2016 Apr; 18(4):424-32. PubMed ID: 26707029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M;
    Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De Ritis ratio as diagnostic marker of alcoholic liver disease.
    Majhi S; Baral N; Lamsal M; Mehta KD
    Nepal Med Coll J; 2006 Mar; 8(1):40-2. PubMed ID: 16827089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.
    Ambrosy AP; Pang PS; Khan S; Konstam MA; Fonarow GC; Traver B; Maggioni AP; Cook T; Swedberg K; Burnett JC; Grinfeld L; Udelson JE; Zannad F; Gheorghiade M;
    Eur Heart J; 2013 Mar; 34(11):835-43. PubMed ID: 23293303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
    Girerd N; Pang PS; Swedberg K; Fought A; Kwasny MJ; Subacius H; Konstam MA; Maggioni A; Gheorghiade M; Zannad F;
    Eur J Heart Fail; 2013 Nov; 15(11):1228-35. PubMed ID: 23787720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
    Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
    J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study.
    van Deursen VM; Edwards C; Cotter G; Davison BA; Damman K; Teerlink JR; Metra M; Felker GM; Ponikowski P; Unemori E; Severin T; Voors AA
    J Card Fail; 2014 Jun; 20(6):407-13. PubMed ID: 24642379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure.
    Nikolaou M; Parissis J; Yilmaz MB; Seronde MF; Kivikko M; Laribi S; Paugam-Burtz C; Cai D; Pohjanjousi P; Laterre PF; Deye N; Poder P; Cohen-Solal A; Mebazaa A
    Eur Heart J; 2013 Mar; 34(10):742-9. PubMed ID: 23091203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M;
    Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
    Blair JE; Khan S; Konstam MA; Swedberg K; Zannad F; Burnett JC; Grinfeld L; Maggioni AP; Udelson JE; Zimmer CA; Ouyang J; Chen CF; Gheorghiade M;
    Eur Heart J; 2009 Jul; 30(13):1666-73. PubMed ID: 19411662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
    O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M;
    Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
    Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M;
    JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study.
    Biegus J; Hillege HL; Postmus D; Valente MA; Bloomfield DM; Cleland JG; Cotter G; Davison BA; Dittrich HC; Fiuzat M; Givertz MM; Massie BM; Metra M; Teerlink JR; Voors AA; O'Connor CM; Ponikowski P
    Eur J Heart Fail; 2016 Jul; 18(7):830-9. PubMed ID: 27170455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
    Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M;
    Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.